Although bone marrow transplantation (BMT) has been a part of clinical practice for more than 30 years, it was only recently realized that hematopoietic cellular infusions used in clinical practice may generate 'unexpected' epithelial cell populations in vivo. 1 Despite the initial skepticism of the reported observations due to methodological limitations, more recent studies using strict criteria and examinations of isolated single cells have clearly shown that following allogeneic hematopoietic cell transplantation (HCT) in humans, graft-derived epithelial cells emerge. 2, 3 The numbers of generated epithelial cells after HCT are low and the underlying mechanism of their occurrence is of major biological significance. Understanding of these mechanisms might be helpful to settle in stem cells for the clinical use of tissue repair. Suggested theories include fusion of donor hematopoietic cells with recipient epithelial cells, generation of epithelial cells from unknown epithelial precursors or universal stem cells, or transdifferentiation of hematopoietic cells. 4 Besides the underlying mechanisms, it is important to trace the cells within the hematopoietic graft that are involved in the development of donor-derived epithelial cells. Hematopoietic grafts contain hematopoietic stem cells, which reside in the CD34-positive fraction capable of establishing a long-term hemopoiesis in the recipient, and other cells, like T cells, mesenchymal cells, dendritic cells or other not better-defined cell populations. The purpose of this study was to analyze whether pure CD34 þ mobilized peripheral blood stem cells (CD34 þ PBSC) are generating epithelial cells in vivo.
Eight female patients who underwent allogeneic HCT with MACS-isolated CD34 þ PBSC (purity 98.3%) from male donors were recruited in the study; methodology was as previously described in our former study on unmanipulated PBSCtransplanted (PBSCT) patients. 4 Briefly, a buccal swab from each patient was obtained at a time point when no mucositis or oral graft-versus-host disease (GvHD) was present, and five cytospins were made from each swab. Four of them were stained with diaminobenzidine (DAB) immunocytochemistry (Sigma, Steinheim, Germany) using either CD45 (HI30, BD, Franklin Lakes, NY, USA), CD3 (SK7, BD), CD15 (MMA, BD) or CD68 (PG-M1, Dako, Glostrup, Denmark) specific antibodies. The fifth slide was stained with a combination of FISH for the X and Y chromosomes (Vysis, Bergisch-Gladbach, Germany), immunofluorescent stain for CK (C-11, FITC-conjugated, Sigma), immunostain for CD45 (2B11 þ PD7/26, Dako) followed by a goat anti-mouse antibody labeled with Alexa Fluor 633 (Molecular Probes, Eugene, OR, USA) and DAPI nuclear counterstain (D-9542, Sigma). The XY/CK/CD45/DAPI-stained slides were evaluated three-dimensionally (3D) by laser-scanning confocal microscopy (TCS/SP2/AOBS, Leica-Microsystems, Germany) and a specialized software (Autovisualize 5.5 (AutoQuant Imaging, USA)) by examiners who had no knowledge of the present or past medical history of the patients. Thereafter, cells were evaluated morphologically by standard hematoxylin/eosin (HE).
We analyzed a mean of 195 buccal cells/patient. Only one patient exhibited a sporadic (Table 1) . This patient had received additionally donor lymphocyte infusions because of mixed chimerism. We compared our present results with the ones from our past study on the PBSCT group; in the former study, we had evaluated a mean of 223 cells/patient, and donor-derived cells were found almost universally (12/13 patients (Po0.0001, Student's t-test)) and in accountable numbers (mean Table 2 ).
Mean age of the patients, preparative regimens, absolute number of CD34 þ cells within the graft, mucositis early post-HCT and history of enoral GvHD did not significantly differ between the two studies ( Table 2 ). All patients in both studies had an initial complete chimerism after transplantation, indicating that transfused CD34 þ cells engrafted well in bone marrow and were fully functional. Mean post-transplantation time of obtaining the buccal swabs differed in the two cohorts (478 in the PBSCT group vs 1705 days in the CD34 þ -selected group). Our previous study revealed a significant correlation between the time of buccal sampling after transplantation and the number of donor-derived epithelial cells, and therefore, if indeed prolonged time after HCT correlates with the extent of epithelial chimerism, one would expect to find more donorderived epithelial cells in our present patient cohort.
The most plausible explanation for the present negative results, as compared to our previous findings in the PBSCT group, is that isolated CD34 þ PBSCs do not generate epithelial cells in vivo. In that case, we have to implicate other cells residing in the graft in the establishment of epithelial chimerism after allogeneic HCT. CD34 þ hematopoietic stem cells are mostly responsible for the long-term repopulation of the bone marrow and the subsequent hemopoiesis in the recipient. However, CD34 þ cells derive from a more 'undifferentiated' CD34-negative fraction, and the expression of CD34 marker in the hematopoietic stem cells is shown to be related to cell cycle activation. 5 Thus, transplantation of isolated CD34 þ cells could have excluded from the graft stem cells that show greater developmental ability for other cell lines, or in other words, the Abbreviations: NS, not significant; GVHD, grant-versus-host disease; HCT, hematopoietic cell transplantation; PBSCT, peripheral blood stem cells transplanted.
Column 'PBSCT group' shows results from our previous published study ( Leukemia (2005) 19, 1287-1289), whereas column 'CD34+ PBSCT group' shows results from our present study. Evaluation of donor-derived epithelial cells for both groups was performed in the same laboratory with the same methodology. Donor-derived epithelial cells were identified as Y + /CK + /CD45 À /DAPI + /HE-E + cells. P-values o0.05 were characterized as significant.
Letters to the Editor cells with higher potential for generating chimeric phenomena could be the more 'primitive' CD34À cells. Recently, a subpopulation of CD45À/LinÀ/CXCR4 þ /Oct-4 þ /Nanog þ /SSEA-1 þ pluripotent stem cells residing in the adult murine bone marrow was described. 6 There is evidence that such cells stay at the top of mesenchymal stem cell hierarchy. 7 A phenotypically similar population of cells are now also reported in human cord blood. 8 It is possible that they also reside in human adult bone marrow and could be mobilized and transfused along with the HSCs, thus being implicated in the development of donorderived epithelial cells.
Epithelial chimerism after allogeneic HCT is a strong motivation for researchers to focus on the developmental potential of stem cells and their possible enrollment in cutting edge tissue-repair therapies. In order to reach this goal, one has to ascertain the underlying mechanisms and define the donor cells involved in the generation of such epithelial chimeric phenomena. Our results indicate that the cell of the hematopoietic graft giving rise to donor-derived epithelial cells after allogeneic HCT is not residing in the CD34 þ fraction.
, which causes cancer through aberrant activation of the Ras/Raf/MEK/MAP kinase/ERK signaling pathway (MAP kinase pathway). [1] [2] [3] Several other uncommon mutations of the BRAF gene are also well characterized and may play an important role in the tumorigenesis of certain human cancers. [1] [2] [3] [4] [5] [6] A recent study reported an interesting T1790A point mutation in exon 15 of the BRAF gene in 10% of patients with childhood acute lymphoblastic leukemia (ALL).
7 This mutation is in codon 597, three codons upstream of codon 600 that carries the conventional T1799A mutation in the BRAF gene. The codon change (CTA to CAA) resulting from this new mutation causes a leucine-to-glutamine amino-acid change (L597Q) in the BRAF protein. Whether this fairly common BRAF L597Q in childhood ALL is functional and oncogenic remains to be determined.
In the present study, we generated the T1790A BRAF mutation through in vitro mutagenesis using wild BRAF in pEFm6 (which, together with the BRAF V600E construct, was a gift from Dr Richard Marais) as the template and appropriately designed primers and the Quick-Change Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA). The mutagenesis primers used were 5 0 -GTAAAAATAGGTGATTTTGGTCAAGCTACAGTGAA ATCTCGATGG-3 0 (forward) and 5 0 -CCATCGAGATTTCACTG TAGCTTGACCAAAATCACCTATTTTTAC-3 0 (reverse) (the nucleotide in italic and bold indicates the mutated site). We performed direct DNA sequencing to verify mutations generated. We first sought to determine the function of BRAF L597Q in activating the MAP kinase signaling pathway. As shown in Figure 1a , (left panel), transient transfection of NIH3T3 cells with these constructs resulted in expression of specific c-mycepitope-tagged BRAF, which was not seen with the control mock (parental NIH3T3 cells) and empty-vector transfections.
